Progyny (NASDAQ:PGNY) versus iSpecimen (NASDAQ:ISPC) Head to Head Contrast

iSpecimen (NASDAQ:ISPC) and Progyny (NASDAQ:PGNY) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their risk, valuation, dividends, analyst recommendations, profitability, institutional ownership and earnings.

Volatility and Risk

iSpecimen has a beta of 1.87, suggesting that its share price is 87% more volatile than the S&P 500. Comparatively, Progyny has a beta of 1.01, suggesting that its share price is 1% more volatile than the S&P 500.

Profitability

This table compares iSpecimen and Progyny’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
iSpecimen	-343.86%	-531.78%	-147.74%
Progyny	4.54%	11.37%	7.73%

Earnings & Valuation

This table compares iSpecimen and Progyny”s revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
iSpecimen	$9.29 million	0.17	-$12.50 million	($7.89)	-0.02
Progyny	$1.29 billion	1.13	$58.52 million	$0.65	27.32

Progyny has higher revenue and earnings than iSpecimen. iSpecimen is trading at a lower price-to-earnings ratio than Progyny, indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a summary of recent ratings and recommmendations for iSpecimen and Progyny, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
iSpecimen	1	0	0	0	1.00
Progyny	0	4	9	0	2.69

Progyny has a consensus price target of $27.91, indicating a potential upside of 57.18%. Given Progyny’s stronger consensus rating and higher possible upside, analysts clearly believe Progyny is more favorable than iSpecimen.

Insider & Institutional Ownership

13.6% of iSpecimen shares are owned by institutional investors. Comparatively, 94.9% of Progyny shares are owned by institutional investors. 12.2% of iSpecimen shares are owned by company insiders. Comparatively, 9.4% of Progyny shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Summary

Progyny beats iSpecimen on 12 of the 14 factors compared between the two stocks.

About iSpecimen

iSpecimen Inc. provides technology that connects life science researchers who need human biofluids, tissues, and living cells for their research with biospecimens available in healthcare provider organizations worldwide. Its cloud-based technology enables scientists to search for specimens and patients across a network of hospitals, clinics, private practice groups, laboratories, blood centers, biobanks, clinical research sites, and cadaveric donation centers. The company develops and operates iSpecimen Marketplace, a proprietary online marketplace platform that connects medical researchers who need access to subjects, samples, and data with hospitals, laboratories, and other organizations who have access to them. It serves biopharmaceutical companies, in vitro diagnostic companies, and government/academic institutions. iSpecimen Inc. was incorporated in 2009 and is headquartered in Lexington, Massachusetts.

About Progyny

Progyny, Inc., a benefits management company, specializes in fertility and family building benefits solutions in the United States. Its fertility benefits solution includes differentiated benefits plan design, personalized concierge-style member support services, and selective network of fertility specialists. The company also offers Progyny Rx, an integrated pharmacy benefits solution that provides its members with access to the medications needed during their treatment. In addition, it provides assistance service programs where various services can be offered through a reimbursement program, including adoption, surrogacy, doula, and travel reimbursement when travel is required to receive medical services. The company was formerly known as Auxogyn, Inc. and changed its name to Progyny, Inc. in 2015. Progyny, Inc. was incorporated in 2008 and is headquartered in New York, New York.